A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

NCT07313761 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
349
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen